|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0013227,
umls-concept:C0016778,
umls-concept:C0030705,
umls-concept:C0041917,
umls-concept:C0144576,
umls-concept:C0205195,
umls-concept:C0278488,
umls-concept:C0920321,
umls-concept:C1527178,
umls-concept:C1561491,
umls-concept:C1705938,
umls-concept:C1709630,
umls-concept:C2603343
|
|
pubmed:issue |
1-2
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
Taxanes and fluoropyrimidines are active in metastatic breast cancer (MBC), and their combination has proven effective in anthracycline-refractory patients. We conducted a phase I study to determine the maximum tolerated dose (MTD) of uracil plus tegafur (UFT) given in combination with leucovorin (LV) and paclitaxel (Pacl) in patients with refractory MBC.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1423-0232
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2007 S. Karger AG, Basel.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
72
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
118-24
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18004083-Adult,
pubmed-meshheading:18004083-Aged,
pubmed-meshheading:18004083-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:18004083-Breast Neoplasms,
pubmed-meshheading:18004083-Cell Line, Tumor,
pubmed-meshheading:18004083-Drug Administration Schedule,
pubmed-meshheading:18004083-Drug Screening Assays, Antitumor,
pubmed-meshheading:18004083-Female,
pubmed-meshheading:18004083-Humans,
pubmed-meshheading:18004083-Leucovorin,
pubmed-meshheading:18004083-Maximum Tolerated Dose,
pubmed-meshheading:18004083-Middle Aged,
pubmed-meshheading:18004083-Models, Theoretical,
pubmed-meshheading:18004083-Neoplasm Metastasis,
pubmed-meshheading:18004083-Paclitaxel,
pubmed-meshheading:18004083-Tegafur,
pubmed-meshheading:18004083-Uracil
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Phase I study of paclitaxel and uracil plus tegafur combination in patients with pretreated metastatic breast cancer: drug sequencing based on preclinical modelling studies.
|
|
pubmed:affiliation |
Department of Medical Oncology, Morgagni-Pierantoni Hospital, Forlì, Italy. sandropass@libero.it
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
